Clorox’s fourth quarter results were met with a negative market reaction, as flat year-on-year sales masked underlying challenges in profitability and margins. Management highlighted that operational ...

Teradyne’s fourth quarter was marked by strong top-line growth and an 11% revenue beat versus Wall Street expectations, ...

Q4 2025 Management View CEO Brian Goff emphasized the company's 2026 strategic priorities, stating, "we're focused on executing a high-impact launch of AQVESME for the treatment of thalassemia in the ...

Q4 2025 Management View CEO Mark Stewart emphasized, "We delivered fourth quarter revenue of $4.9 billion, and segment operating income of $416 million, which represents year-on-year organic growth of ...

DOGE shows seller fatigue with TD Sequential 9 setup; price stabilizes near $0.090, signaling potential recovery ahead.

Dogecoin flashes TD Sequential buy signal at $0.09 support. Analysts eye potential rebound after 18% weekly drop and ...

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Q2 2026 Earnings Call February 10, 2026 8:00 AM ESTCompany ParticipantsMartin Beer - CFO & Member of Management ...